The Ohio State University (OSU) postdoctoral oncology training program is designed to produce physician-scientists and basic scientists capable of conducting independent research related to cancer treatment and prevention. Trainees will be selected from motivated and gifted M.D., D.O., or Ph.D. candidates who are committed to careers in patient- oriented cancer research. Trainees with health professional degrees will be selected from programs in medical, pediatric, surgical, and/or radiation oncology, and will have completed their clinical subspecialty training. To be selected, physician candidates will need to demonstrate an appreciation of the need for physician-scientists to link the bench with the bedside. Candidates possessing the Ph.D. degree will be chosen from basic science programs of biochemistry, molecular genetics, microbiology and immunology, pharmacology, virology, cellular biology, mathematics, physics, or other programs which have prepared and stimulated the candidates to translate their basic research toward the solution of clinical cancer research questions. The training program will require to two to three years. Trainees will have independent research projects within a training faculty laboratory. All training faculty are members of one of eight Comprehensive Cancer Center (CCC) Programs of: molecular biology and cancer genetics, immunology, developmental therapeutics, hormones and cancer, molecular carcinogenesis, cancer prevention and control, RNA tumor viruses, or neuro-oncology. The 46 training faculty and the 12 contributing faculty are all NIH/ACS-funded basic scientists and physician-investigators who have developed a network of collaborative interactions within the CCC which expose the trainee to multiple research perspectives and expertise The same faculty participate with trainees in joint conferences which further enhance appreciation of different research approaches. Formal courses assist the trainee in developing an appropriate knowledge base. The new Division of Human Cancer Genetics and revitalized Division of Hematology-Oncology within the OSU CC has resulted in 18 new faculty recruitments during the past academic year, with 10 more faculty positions in these two Divisions to be filled in the current academic year, all with a cancer focus. This competitive renewal application seeks support for 10 trainees by the end of the fifth year of funding with 7 or 8 of those being physician-trainees.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA009338-23
Application #
6375516
Study Section
Subcommittee G - Education (NCI)
Project Start
1978-07-01
Project End
2004-06-30
Budget Start
2001-09-10
Budget End
2002-06-30
Support Year
23
Fiscal Year
2001
Total Cost
$407,684
Indirect Cost
Name
Ohio State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Abbaoui, Besma; Lucas, Christopher R; Riedl, Ken M et al. (2018) Cruciferous Vegetables, Isothiocyanates, and Bladder Cancer Prevention. Mol Nutr Food Res 62:e1800079
Mace, Thomas A; Shakya, Reena; Pitarresi, Jason R et al. (2018) IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut 67:320-332
Victor, Aaron R; Weigel, Christoph; Scoville, Steven D et al. (2018) Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development. J Immunol 200:565-572
Latchana, Nicholas; DiVincenzo, Mallory J; Regan, Kelly et al. (2018) Alterations in patient plasma microRNA expression profiles following resection of metastatic melanoma. J Surg Oncol 118:501-509
Zitzer, Nina C; Snyder, Katiri; Meng, Xiamoei et al. (2018) MicroRNA-155 Modulates Acute Graft-versus-Host Disease by Impacting T Cell Expansion, Migration, and Effector Function. J Immunol 200:4170-4179
Chan, Wing Keung; Kang, Siwen; Youssef, Youssef et al. (2018) A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma. Cancer Immunol Res 6:776-787
Smith, Emily; Zhou, Wei; Shindiapina, Polina et al. (2018) Recent advances in targeting protein arginine methyltransferase enzymes in cancer therapy. Expert Opin Ther Targets 22:527-545
Park, I-K; Blum, W; Baker, S D et al. (2017) E3 ubiquitin ligase Cbl-b activates the p53 pathway by targeting Siva1, a negative regulator of ARF, in FLT3 inhibitor-resistant acute myeloid leukemia. Leukemia 31:502-505
Abbaoui, Besma; Telu, Kelly H; Lucas, Christopher R et al. (2017) The impact of cruciferous vegetable isothiocyanates on histone acetylation and histone phosphorylation in bladder cancer. J Proteomics 156:94-103
McMichael, Elizabeth L; Jaime-Ramirez, Alena Cristina; Guenterberg, Kristan D et al. (2017) IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells. Clin Cancer Res 23:489-502

Showing the most recent 10 out of 138 publications